AMB-FUBINACA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H22FN3O3 |
| Molar mass | 383.42 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1][2][3] It was originally developed by Pfizer which described the compound in a patent in 2009, but was later abandoned and never tested on humans.[4]
Mass casualties
On July 12, 2016 the New York City Emergency Medical Services (EMS) responded[5] to a "mass casualty event" in Brooklyn, New York, [6] where 33 people ranging in age from 25 to 59 years old were adversely affected by the drug.[5] 18 were hospitalized.[5] All of the victims were described by by-standers as “zombielike” and the cause was attributed to use of AMB-FUBINACA as the demethylated metabolite was found in the blood and urine of eight of the hospitalized patients that had been sent for testing by the DEA. Screening for the more usual drugs of abuse was negative in all 8 patients. AMB-FUBINACA itself was found in a sample from the product smoked by another patient. The metabolite was identified after 10 days and the AMB-FUBINACA was only confirmed 17 days after the incident.[5]
Legal status
The state of Louisiana banned AMB-FUBINACA through an emergency rule after it was detected in a synthetic cannabis product called "Train Wreck 2" which had been linked to adverse events and seizures on 3 June 2014.[7]
Sweden's public health agency suggested classifying AMB-FUBINACA as a hazardous substance on November 10, 2014.[8]
See also
References
- ^ "FUB-AMB". Cayman Chemical. Retrieved 21 July 2015.
- ^ Shigeki Akamatsu; Masashi Yoshida (January 2016). "Fragmentation of synthetic cannabinoids with an isopropyl group or a tert-butyl group ionized by electron impact and electrospray". Journal of Mass Spectrometry. 51 (1): 28–32. doi:10.1002/jms.3722.
- ^ Samuel D Banister; et al. (July 2016). "The pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues". ACS Chemical Neuroscience. 7: 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
{{cite journal}}: Explicit use of et al. in:|author1=(help) - ^ Santora, Marc (2016-12-14). "Drug 85 Times as Potent as Marijuana Caused a 'Zombielike' State in Brooklyn". The New York Times. ISSN 0362-4331. Retrieved 2016-12-15.
- ^ a b c d Adams, Axel J.; Banister, Samuel D.; Irizarry, Lisandro; Trecki, Jordan; Schwartz, Michael; Gerona, Roay (14 December 2016). ""Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York" (PDF). New England Journal of Medicine. doi:10.1056/NEJMoa1610300. Retrieved 15 December 2016.
- ^ Santora, Mark. "Drug 85 Times as Potent as Marijuana Caused a 'Zombielike' State in Brooklyn". New York Times. Retrieved 15 December 2016.
- ^ "DHH Adds Two New Synthetic Marijuana Compounds to Banned List". Louisiana Department of Health and Hospitals. 3 June 2014. Retrieved 21 July 2015.
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. Retrieved 21 July 2015.
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |